Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 96

1.

Distinct dual antiviral mechanism that enhances hepatitis B virus mutagenesis and reduces viral DNA synthesis.

McDaniel YZ, Patterson SE, Mansky LM.

Antiviral Res. 2019 Jun 25;170:104540. doi: 10.1016/j.antiviral.2019.104540. [Epub ahead of print]

PMID:
31247245
2.

Correction to: The Retrovirus Capsid Core.

Zhang W, Mendonça LM, Mansky LM.

Subcell Biochem. 2018;88:E1. doi: 10.1007/978-981-10-8456-0_18.

PMID:
30488398
3.

Human T-cell leukemia virus type 1 Gag domains have distinct RNA-binding specificities with implications for RNA packaging and dimerization.

Wu W, Hatterschide J, Syu YC, Cantara WA, Blower RJ, Hanson HM, Mansky LM, Musier-Forsyth K.

J Biol Chem. 2018 Oct 19;293(42):16261-16276. doi: 10.1074/jbc.RA118.005531. Epub 2018 Sep 14.

PMID:
30217825
4.

Distinct Pathway of Human T-Cell Leukemia Virus Type 1 Gag Punctum Biogenesis Provides New Insights into Enveloped Virus Assembly.

Eichorst JP, Chen Y, Mueller JD, Mansky LM.

MBio. 2018 Sep 4;9(5). pii: e00758-18. doi: 10.1128/mBio.00758-18.

5.
6.

The Retrovirus Capsid Core.

Zhang W, Mendonça LM, Mansky LM.

Subcell Biochem. 2018;88:169-187. doi: 10.1007/978-981-10-8456-0_8. Review. Erratum in: Subcell Biochem. 2018;88:E1.

PMID:
29900497
7.

Critical Role of the Human T-Cell Leukemia Virus Type 1 Capsid N-Terminal Domain for Gag-Gag Interactions and Virus Particle Assembly.

Martin JL, Mendonça LM, Marusinec R, Zuczek J, Angert I, Blower RJ, Mueller JD, Perilla JR, Zhang W, Mansky LM.

J Virol. 2018 Jun 29;92(14). pii: e00333-18. doi: 10.1128/JVI.00333-18. Print 2018 Jul 15.

8.

Perturbation of Human T-Cell Leukemia Virus Type 1 Particle Morphology by Differential Gag Co-Packaging.

Maldonado JO, Angert I, Cao S, Berk S, Zhang W, Mueller JD, Mansky LM.

Viruses. 2017 Jul 19;9(7). pii: E191. doi: 10.3390/v9070191.

9.

Polymorphic Nature of Human T-Cell Leukemia Virus Type 1 Particle Cores as Revealed through Characterization of a Chronically Infected Cell Line.

Meissner ME, Mendonça LM, Zhang W, Mansky LM.

J Virol. 2017 Jul 27;91(16). pii: e00369-17. doi: 10.1128/JVI.00369-17. Print 2017 Aug 15.

10.

Single-Strand Consensus Sequencing Reveals that HIV Type but not Subtype Significantly Impacts Viral Mutation Frequencies and Spectra.

Rawson JMO, Gohl DM, Landman SR, Roth ME, Meissner ME, Peterson TS, Hodges JS, Beckman KB, Mansky LM.

J Mol Biol. 2017 Jul 21;429(15):2290-2307. doi: 10.1016/j.jmb.2017.05.010. Epub 2017 May 11.

11.

Disparate Contributions of Human Retrovirus Capsid Subdomains to Gag-Gag Oligomerization, Virus Morphology, and Particle Biogenesis.

Martin JL, Mendonça LM, Angert I, Mueller JD, Zhang W, Mansky LM.

J Virol. 2017 Jun 26;91(14). pii: e00298-17. doi: 10.1128/JVI.00298-17. Print 2017 Jul 15.

12.

Distinct Particle Morphologies Revealed through Comparative Parallel Analyses of Retrovirus-Like Particles.

Martin JL, Cao S, Maldonado JO, Zhang W, Mansky LM.

J Virol. 2016 Aug 26;90(18):8074-84. doi: 10.1128/JVI.00666-16. Print 2016 Sep 15.

13.

Distinct Morphology of Human T-Cell Leukemia Virus Type 1-Like Particles.

Maldonado JO, Cao S, Zhang W, Mansky LM.

Viruses. 2016 May 11;8(5). pii: E132. doi: 10.3390/v8050132.

14.

Synergistic reduction of HIV-1 infectivity by 5-azacytidine and inhibitors of ribonucleotide reductase.

Rawson JM, Roth ME, Xie J, Daly MB, Clouser CL, Landman SR, Reilly CS, Bonnac L, Kim B, Patterson SE, Mansky LM.

Bioorg Med Chem. 2016 Jun 1;24(11):2410-22. doi: 10.1016/j.bmc.2016.03.052. Epub 2016 Mar 30.

PMID:
27117260
15.

Dual anti-HIV mechanism of clofarabine.

Daly MB, Roth ME, Bonnac L, Maldonado JO, Xie J, Clouser CL, Patterson SE, Kim B, Mansky LM.

Retrovirology. 2016 Mar 24;13:20. doi: 10.1186/s12977-016-0254-0.

16.

5-Azacytidine Enhances the Mutagenesis of HIV-1 by Reduction to 5-Aza-2'-Deoxycytidine.

Rawson JM, Daly MB, Xie J, Clouser CL, Landman SR, Reilly CS, Bonnac L, Kim B, Patterson SE, Mansky LM.

Antimicrob Agents Chemother. 2016 Mar 25;60(4):2318-25. doi: 10.1128/AAC.03084-15. Print 2016 Apr.

17.

Molecular Studies of HTLV-1 Replication: An Update.

Martin JL, Maldonado JO, Mueller JD, Zhang W, Mansky LM.

Viruses. 2016 Jan 27;8(2). pii: E31. doi: 10.3390/v8020031. Review.

18.

Rapid Determination of HIV-1 Mutant Frequencies and Mutation Spectra Using an mCherry/EGFP Dual-Reporter Viral Vector.

Rawson JM, Clouser CL, Mansky LM.

Methods Mol Biol. 2016;1354:71-88. doi: 10.1007/978-1-4939-3046-3_6.

PMID:
26714706
19.

Morphology and ultrastructure of retrovirus particles.

Zhang W, Cao S, Martin JL, Mueller JD, Mansky LM.

AIMS Biophys. 2015;2(3):343-369. Epub 2015 Aug 18.

20.

Lack of mutational hot spots during decitabine-mediated HIV-1 mutagenesis.

Rawson JM, Landman SR, Reilly CS, Bonnac L, Patterson SE, Mansky LM.

Antimicrob Agents Chemother. 2015 Nov;59(11):6834-43. doi: 10.1128/AAC.01644-15. Epub 2015 Aug 17.

21.

HIV-1 and HIV-2 exhibit similar mutation frequencies and spectra in the absence of G-to-A hypermutation.

Rawson JM, Landman SR, Reilly CS, Mansky LM.

Retrovirology. 2015 Jul 10;12:60. doi: 10.1186/s12977-015-0180-6.

22.

Analysis of human T-cell leukemia virus type 1 particles by using cryo-electron tomography.

Cao S, Maldonado JO, Grigsby IF, Mansky LM, Zhang W.

J Virol. 2015 Feb;89(4):2430-5. doi: 10.1128/JVI.02358-14. Epub 2014 Dec 3.

23.

Retroviral vectors for analysis of viral mutagenesis and recombination.

Rawson JM, Mansky LM.

Viruses. 2014 Sep 24;6(9):3612-42. doi: 10.3390/v6093612. Review.

24.

Novel inhibitors of human immunodeficiency virus type 2 infectivity.

Beach LB, Rawson JM, Kim B, Patterson SE, Mansky LM.

J Gen Virol. 2014 Dec;95(Pt 12):2778-83. doi: 10.1099/vir.0.069864-0. Epub 2014 Aug 7.

25.

New insights into retroviral Gag-Gag and Gag-membrane interactions.

Maldonado JO, Martin JL, Mueller JD, Zhang W, Mansky LM.

Front Microbiol. 2014 Jun 24;5:302. doi: 10.3389/fmicb.2014.00302. eCollection 2014. Review.

26.

Anti-HIV-1 activity of Trim 37.

Tabah AA, Tardif K, Mansky LM.

J Gen Virol. 2014 Apr;95(Pt 4):960-7. doi: 10.1099/vir.0.057653-0. Epub 2013 Dec 6.

27.

Interrelationship between cytoplasmic retroviral Gag concentration and Gag-membrane association.

Fogarty KH, Berk S, Grigsby IF, Chen Y, Mansky LM, Mueller JD.

J Mol Biol. 2014 Apr 3;426(7):1611-24. doi: 10.1016/j.jmb.2013.11.025. Epub 2013 Dec 4.

28.

Retrovirus-specific differences in matrix and nucleocapsid protein-nucleic acid interactions: implications for genomic RNA packaging.

Sun M, Grigsby IF, Gorelick RJ, Mansky LM, Musier-Forsyth K.

J Virol. 2014 Jan;88(2):1271-80. doi: 10.1128/JVI.02151-13. Epub 2013 Nov 13.

29.

Discovery of novel ribonucleoside analogs with activity against human immunodeficiency virus type 1.

Dapp MJ, Bonnac L, Patterson SE, Mansky LM.

J Virol. 2014 Jan;88(1):354-63. doi: 10.1128/JVI.02444-13. Epub 2013 Oct 23.

30.

5,6-Dihydro-5-aza-2'-deoxycytidine potentiates the anti-HIV-1 activity of ribonucleotide reductase inhibitors.

Rawson JM, Heineman RH, Beach LB, Martin JL, Schnettler EK, Dapp MJ, Patterson SE, Mansky LM.

Bioorg Med Chem. 2013 Nov 15;21(22):7222-8. doi: 10.1016/j.bmc.2013.08.023. Epub 2013 Aug 20.

31.

Characterization of permeability, stability and anti-HIV-1 activity of decitabine and gemcitabine divalerate prodrugs.

Clouser CL, Bonnac L, Mansky LM, Patterson SE.

Antivir Chem Chemother. 2014 Dec 16;23(6):223-30. doi: 10.3851/IMP2682.

32.

Structure-activity relationships and design of viral mutagens and application to lethal mutagenesis.

Bonnac LF, Mansky LM, Patterson SE.

J Med Chem. 2013 Dec 12;56(23):9403-14. doi: 10.1021/jm400653j. Epub 2013 Aug 26. Review.

PMID:
23914828
33.

APOBEC3G cytosine deamination hotspots are defined by both sequence context and single-stranded DNA secondary structure.

Holtz CM, Sadler HA, Mansky LM.

Nucleic Acids Res. 2013 Jul;41(12):6139-48. doi: 10.1093/nar/gkt246. Epub 2013 Apr 24.

34.

Variation of HIV-1 mutation spectra among cell types.

Holtz CM, Mansky LM.

J Virol. 2013 May;87(9):5296-9. doi: 10.1128/JVI.03576-12. Epub 2013 Feb 28.

35.

Back to the future: revisiting HIV-1 lethal mutagenesis.

Dapp MJ, Patterson SE, Mansky LM.

Trends Microbiol. 2013 Feb;21(2):56-62. doi: 10.1016/j.tim.2012.10.006. Epub 2012 Nov 27.

36.

Interrelationship between HIV-1 fitness and mutation rate.

Dapp MJ, Heineman RH, Mansky LM.

J Mol Biol. 2013 Jan 9;425(1):41-53. doi: 10.1016/j.jmb.2012.10.009. Epub 2012 Oct 16.

37.

Anti-HIV-1 activity of resveratrol derivatives and synergistic inhibition of HIV-1 by the combination of resveratrol and decitabine.

Clouser CL, Chauhan J, Bess MA, van Oploo JL, Zhou D, Dimick-Gray S, Mansky LM, Patterson SE.

Bioorg Med Chem Lett. 2012 Nov 1;22(21):6642-6. doi: 10.1016/j.bmcl.2012.08.108. Epub 2012 Sep 6.

38.

Concomitant lethal mutagenesis of human immunodeficiency virus type 1.

Dapp MJ, Holtz CM, Mansky LM.

J Mol Biol. 2012 Jun 8;419(3-4):158-70. doi: 10.1016/j.jmb.2012.03.003. Epub 2012 Mar 15.

39.

Activity of a novel combined antiretroviral therapy of gemcitabine and decitabine in a mouse model for HIV-1.

Clouser CL, Holtz CM, Mullett M, Crankshaw DL, Briggs JE, O'Sullivan MG, Patterson SE, Mansky LM.

Antimicrob Agents Chemother. 2012 Apr;56(4):1942-8. doi: 10.1128/AAC.06161-11. Epub 2012 Jan 23.

40.

Discovery of drugs that possess activity against feline leukemia virus.

Greggs WM 3rd, Clouser CL, Patterson SE, Mansky LM.

J Gen Virol. 2012 Apr;93(Pt 4):900-5. doi: 10.1099/vir.0.039909-0. Epub 2012 Jan 18.

41.

Recruitment of the nuclear form of uracil DNA glycosylase into virus particles participates in the full infectivity of HIV-1.

Guenzel CA, Hérate C, Le Rouzic E, Maidou-Peindara P, Sadler HA, Rouyez MC, Mansky LM, Benichou S.

J Virol. 2012 Mar;86(5):2533-44. doi: 10.1128/JVI.05163-11. Epub 2011 Dec 14.

42.

New insights into HTLV-1 particle structure, assembly, and Gag-Gag interactions in living cells.

Fogarty KH, Zhang W, Grigsby IF, Johnson JL, Chen Y, Mueller JD, Mansky LM.

Viruses. 2011 Jun;3(6):770-93. doi: 10.3390/v3060770. Epub 2011 Jun 14. Review.

43.

Broadening the use of antiretroviral therapy: the case for feline leukemia virus.

Greggs WM 3rd, Clouser CL, Patterson SE, Mansky LM.

Ther Clin Risk Manag. 2011;7:115-22. doi: 10.2147/TCRM.S17731. Epub 2011 Mar 16.

44.

A virus-binding hot spot on human angiotensin-converting enzyme 2 is critical for binding of two different coronaviruses.

Wu K, Chen L, Peng G, Zhou W, Pennell CA, Mansky LM, Geraghty RJ, Li F.

J Virol. 2011 Jun;85(11):5331-7. doi: 10.1128/JVI.02274-10. Epub 2011 Mar 16.

45.

Characterization of cytoplasmic Gag-gag interactions by dual-color z-scan fluorescence fluctuation spectroscopy.

Fogarty KH, Chen Y, Grigsby IF, Macdonald PJ, Smith EM, Johnson JL, Rawson JM, Mansky LM, Mueller JD.

Biophys J. 2011 Mar 16;100(6):1587-95. doi: 10.1016/j.bpj.2011.02.008.

46.

Analysis of the ex vivo and in vivo antiretroviral activity of gemcitabine.

Clouser CL, Holtz CM, Mullett M, Crankshaw DL, Briggs JE, Chauhan J, VanHoutan IM, Patterson SE, Mansky LM.

PLoS One. 2011 Jan 14;6(1):e15840. doi: 10.1371/journal.pone.0015840.

47.

Triterpene derivatives that inhibit human immunodeficiency virus type 1 replication.

Dorr CR, Yemets S, Kolomitsyna O, Krasutsky P, Mansky LM.

Bioorg Med Chem Lett. 2011 Jan 1;21(1):542-5. doi: 10.1016/j.bmcl.2010.10.078.

48.

Human pluripotent stem cells produce natural killer cells that mediate anti-HIV-1 activity by utilizing diverse cellular mechanisms.

Ni Z, Knorr DA, Clouser CL, Hexum MK, Southern P, Mansky LM, Park IH, Kaufman DS.

J Virol. 2011 Jan;85(1):43-50. doi: 10.1128/JVI.01774-10. Epub 2010 Oct 20.

49.

Biophysical analysis of HTLV-1 particles reveals novel insights into particle morphology and Gag stochiometry.

Grigsby IF, Zhang W, Johnson JL, Fogarty KH, Chen Y, Rawson JM, Crosby AJ, Mueller JD, Mansky LM.

Retrovirology. 2010 Sep 20;7:75. doi: 10.1186/1742-4690-7-75.

50.

Viral mutation rates.

Sanjuán R, Nebot MR, Chirico N, Mansky LM, Belshaw R.

J Virol. 2010 Oct;84(19):9733-48. doi: 10.1128/JVI.00694-10. Epub 2010 Jul 21. Review.

Supplemental Content

Loading ...
Support Center